Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects

Lipids

Volumn 45, Issue 12, 2010, Pages 1117-1126

  Tchoua, Urbain ^a   Rosales, Corina ^a   Tang, Daming ^a   Gillard, Baiba K ^a   Vaughan, Ashley ^b   Lin, Hu Yu ^a   Courtney, Harry S ^c   Pownall, Henry J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cholesterol efflux; Cholesteryl esters; HDL; LCAT; Neo HDL; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; BACTERIAL PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SERUM OPACITY FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYSIS; CELL STRAIN BHK; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; GENE OVEREXPRESSION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; CRICETINAE; ESTERIFICATION; HUMANS; INFLAMMATION; MACROPHAGES; PEPTIDE HYDROLASES; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 78651067360     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-010-3484-2     Document Type: Article

References (38)

1. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V (2003) Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245
2. Manninen V, Elo MO, Frick M, Haapa K, Heinonen OP, Heinsalm P, Helo P, Huttunen JK, Kaitaniem P, Koskinen P (1988) Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA 260:641-651
3. Rhoads GG, Gulbrandsen CL, Kagan A (1976) Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 294:293-298
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. Am J Med 66:707-714
5. Miller NE, Thelle DS, Førde OH, Mjøs OD (1977) The Tromsø heart study: high-density lipoprotein and coronary heart-disease: A prospective case-control study. Lancet 1:964-968
6. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqu MH, Tyroler HA (1990) High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The followup study of the lipid research clinics prevalence study. Am J Epidemiol 131:32-47
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer HB (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357L:2109-2122
8. Cuchel M, Rader DJ (2006) Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113:2548-2555
9. Courtney HS, Zhang YM, Frank MW, Rock CO (2006) Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure. J Biol Chem 281:5515-5521
10. Gillard BK, Courtney HS, Massey JB, Pownall HJ (2007) Serum opacity factor unmasks human plasma high density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption. Biochemistry 46:12968-12978
11. Pownall HJ, Courtney HS, Gillard BK, Massey JB (2008) Properties of the products formed by the activity of serum opacity factor against human plasma high density lipoproteins. Chem Phys Lipids 156:45-51
12. Han M, Gillard BK, Courtney HS, Ward K, Rosales C, Khant H, Ludtke SJ, Pownall HJ (2009) Disruption of human plasma high density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I. Biochemistry 48:1481-1487
13. Picardo M, Massey JB, Kuhn DE, Gotto AM Jr, Gianturco SH, Pownall HJ (1986) Partially reassembled high density lipoproteins effects on cholesterol flux, synthesis, and esterification in normal human skin fibroblasts. Arteriosclerosis 6:434-441
14. Yancey PG, De la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH (2000) High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 275:36596-36604
15. Tchoua U, Gillard BK, Pownall HJ (2010) HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis 209:430-435
16. Pownall HJ (2006) Detergent-mediated phospholipidation of plasma lipoproteins increases HDL cholesterophilicity and cholesterol efflux via SR-BI. Biochemistry 45(38):11514-11522
17. Steinbrecher UP (1987) Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 262:3603-3608
18. Mukhamedova N, Escher G, D'Souza W, Tchoua U, Grant A, Krozowski Z, Bukrinsky M, Sviridov D (2008) Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. J Lipid Res 49:2312-2322
19. Vaughan AM, Oram JF (2006) ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res 47:2433-2443
20. Lund-Katz S, Hammerschlag B, Phillips MC (1982) Kinetics and mechanism of free cholesterol exchange between human serum high- and low-density lipoproteins. Biochemistry 21:2964-2969
21. Massey JB, Hickson D, She HS, Sparrow JT, Via DP, Gotto AM Jr, Pownall HJ (1984) Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Biochim Biophys Acta 794:274-280
22. Pownall HJ, Bick DL, Massey JB (1991) Spontaneous phospholipid transfer: development of a quantitative model. Biochemistry 30:5696-5700
23. Pownall HJ, Brauchi D, Kilinç C, Osmundsen K, Pao Q, Payton- Ross C, Gotto AM, Ballantyne CM (1999) Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143:285-297
24. Davidson WS, Rodriguez WV, Lund-Katz S, Johnson WJ, Rothblat GH, Phillips MC (1995) Effects of acceptor particle size on the efflux of cellular free cholesterol. J Biol Chem 270:17106-17113
25. Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund- Katz S, Adorni MP, Phillips MC, Rothblat GH (2009) Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res 50:275-284
26. Wang N, Lan D, Chen W, Matsuura F, Tall AR (2004) ATPbinding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101:9774-9779
27. Duong PT, Weibel GL, Lund-Katz S, Rothblat GH, Phillips MC (2008) Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apo A-I. J Lipid Res 49:1006-1014
28. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30:796-801
29. Chen CH, Albers JJ (1982) Distribution of lecithin-cholesterol acyltransferase (LCAT) in human plasma lipoprotein fractions evidence for the association of active LCAT with low density lipoproteins. Biochem Biophys Res Commun 107:1091-1096
30. Aron L, Jones S, Fielding CJ (1978) Human plasma lecithincholesterol acyltransferase: characterization of cofactor-dependent phospholipase activity. J Biol Chem 253:7220-7226
31. Havel RJ, Goldstein JL, Brown MS, Bondy PK, Rosenberg LE (1980) Lipoproteins and lipid transport in the context of metabolic disease. Saunders Publishing, Philadelphia, pp 393-494
32. Gillard BK, Rosales C, Lin H-Y, Courtney HS, Pownall HJ (2010) Treatment of human HDL with serum opacity factor increases the rate of cholesterol ester uptake by human hepatoma cells. Biochemistry (in press)
33. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM (2004) Antiinflammatory properties of HDL. Circ Res 95(8):764-772
34. Robbesyn F, Garcia V, Auge N, Vieira O, Frisach MF, Salvayre R, Negre-Salvarye A (2003) HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 17(6):743-745
35. Tall AR (2008) Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 263(3):256-273
36. Rader DJ (2007) Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 4:102-109
37. Tabas I (2005) Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 25:2255-2264
38. Tanigawa H, Billheimer JT, Tohyama J, Fuki IV, Ng DS, Rothblat GH, Rader DJ (2009) Lecithin-cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 120:160-169